1. Search Result
Search Result
Results for "

Noncompetitive

" in MedChemExpress (MCE) Product Catalog:

622

Inhibitors & Agonists

2

Biochemical Assay Reagents

27

Peptides

3

Inhibitory Antibodies

117

Natural
Products

37

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15084
    Dizocilpine maleate
    40+ Cited Publications

    (+)-MK 801 Maleate

    iGluR Neurological Disease
    Dizocilpine maleate (MK-801 maleate) is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
    Dizocilpine maleate
  • HY-15084B
    Dizocilpine
    40+ Cited Publications

    MK-801

    iGluR Neurological Disease
    Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
    Dizocilpine
  • HY-15251
    Reparixin
    60+ Cited Publications

    Repertaxin; DF 1681Y

    CXCR Inflammation/Immunology Endocrinology Cancer
    Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
    Reparixin
  • HY-12755
    ML141
    30+ Cited Publications

    CID-2950007

    Ras Apoptosis Cancer
    ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines .
    ML141
  • HY-138630
    AG-270
    5+ Cited Publications

    Methionine Adenosyltransferase (MAT) Cancer
    AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM .
    AG-270
  • HY-17353
    BIBR 1532
    5+ Cited Publications

    Telomerase Apoptosis Cancer
    BIBR 1532 is a potent, selective and non-competitive telomerase inhibitor with IC50 of 100 nM in a cell-free assay.
    BIBR 1532
  • HY-W015611

    Endogenous Metabolite Metabolic Disease
    L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion.
    L-(+)-Arabinose
  • HY-10809
    Bitopertin
    2 Publications Verification

    RG1678; RO4917838

    GlyT Neurological Disease
    Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human GlyT1 with a concentration exhibiting IC50 of 25 nM.
    Bitopertin
  • HY-13290
    KN-62
    10+ Cited Publications

    CaMK P2X Receptor Metabolic Disease Cancer
    KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a Ki of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
    KN-62
  • HY-100386
    Ticlopidine
    3 Publications Verification

    PCR 5332

    NTPDase Cytochrome P450 Cardiovascular Disease
    Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.
    Ticlopidine
  • HY-106697
    Ponalrestat
    1 Publications Verification

    ICI 128436

    Aldose Reductase Metabolic Disease
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol .
    Ponalrestat
  • HY-12042
    Pimasertib
    5+ Cited Publications

    AS703026; MSC1936369B

    MEK Cancer
    Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor .
    Pimasertib
  • HY-N0457A
    L-Chicoric Acid
    3 Publications Verification

    (-)-Chicoric acid; trans-Caffeoyltartaric acid

    HIV Integrase HIV Endogenous Metabolite Infection Cancer
    L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC50 of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .
    L-Chicoric Acid
  • HY-13986
    Merimepodib
    2 Publications Verification

    VX-497; MMPD

    Flavivirus Dengue Virus HBV HCV Infection Cancer
    Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
    Merimepodib
  • HY-W010510

    2-Aminopentanoic acid

    Endogenous Metabolite Arginase Metabolic Disease
    DL-Norvaline, a derivative of L-norvaline, L-norvaline is a non-competitive inhibitor of arginase.
    DL-Norvaline
  • HY-148394
    UCK2 Inhibitor-1
    2 Publications Verification

    DNA/RNA Synthesis Cancer
    UCK2 Inhibitor-1 (Compound 20874830-2) is a non-competitive UCK2 inhibitor with an IC50 of 4.7 μM. UCK2 Inhibitor-1 acts as a non-competitive inhibitor against uridine and ATP, and functionally inhibits the enzymatic activity of UCK2. UCK2 Inhibitor-1 suppresses the uridine salvage pathway. UCK2 Inhibitor-1 can be used in chronic myeloid leukemia research .
    UCK2 Inhibitor-1
  • HY-Y0504

    Hegzadesil; Trimethylamine hydrochloric acid; Trimethylamine monohydrochloride

    Environmental Pollutants Cholinesterase (ChE) Endogenous Metabolite Metabolic Disease
    Trimethylammonium chloride (Hegzadesil) is a non-competitive Acetylcholinesterase inhibitor. Trimethylammonium chloride reversibly blocks the deacetylation of acetylcholinesterase .
    Trimethylammonium chloride
  • HY-B1786
    Sulindac sulfide
    1 Publications Verification

    cis-Sulindac sulfide

    Drug Metabolite γ-secretase Neurological Disease
    Sulindac sulfide is a noncompetitive γ-secretase inhibitor, with an IC50 of 20.2 μM for γ42-secretase activity.
    Sulindac sulfide
  • HY-P1095

    Caspase-3 Inhibitor VII

    Caspase Cardiovascular Disease Neurological Disease
    Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC50 of 23 nM. Ivachtin has modest selectivity for the remaining caspases .
    Ivachtin
  • HY-128358
    MR-L2
    1 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease
    MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM .
    MR-L2
  • HY-12895
    SKI V
    1 Publications Verification

    SphK PI3K Apoptosis Cancer
    SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity .
    SKI V
  • HY-N1386

    Tyrosinase Metabolic Disease
    2-Methoxycinnamic acid is a noncompetitive inhibitor of tyrosinase .
    2-Methoxycinnamic acid
  • HY-102095

    mGluR Neurological Disease
    SIB-1757 is a highly selective and noncompetitive antagonist of mGlu5 receptor with an IC50 of 0.4 μM .
    SIB-1757
  • HY-139319
    LDHA-IN-3
    2 Publications Verification

    Lactate Dehydrogenase Cancer
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
    LDHA-IN-3
  • HY-107711
    DQP-1105
    1 Publications Verification

    iGluR Neurological Disease
    DQP-1105 is a potent noncompetitive NMDA receptor antagonist. DQP-1105 inhibits GluN2C- and GluN2D-containing receptors (IC50=7.0 and 2.7 μM, respectively). The IC50 values are at least 50-fold lower than those for recombinant GluN2A-, GluN2B-, GluA1-, or GluK2-containing receptors .
    DQP-1105
  • HY-100386R

    PCR 5332 (Standard)

    Reference Standards NTPDase Cytochrome P450 Cardiovascular Disease
    Ticlopidine (Standard) is the analytical standard of Ticlopidine. This product is intended for research and analytical applications. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively .
    Ticlopidine (Standard)
  • HY-N2735

    Influenza Virus Infection Inflammation/Immunology
    7,3',4'-Trihydroxy-3-benzyl-2H-chromene is an reversible noncompetitive neuraminidase (NA) inhibitor. 7,3',4'-Trihydroxy-3-benzyl-2H-chromene can be isolated from the dried heartwood of Caesalpinia sappan L. 7,3',4'-Trihydroxy-3-benzyl-2H-chromene has potent NAs inhibitory activities with IC50 values of 34.6 µM [H1N1], 39.5 µM [H3N2], and 50.5µM [H9N2], respectively. 7,3',4'-Trihydroxy-3-benzyl-2H-chromene can be used for the research of influenza virus .
    7,3',4'-Trihydroxy-3-benzyl-2H-chromene
  • HY-176550

    Sodium Channel Neurological Disease
    ASIC1a antagonist-1 (Compound 5b) is an orthosteric noncompetitive Acid sensing ion channels 1a (ASIC1a) antagonist with an IC50 of 27 nM (pH 6.7). ASIC1a antagonist-1 shifts pH dependence of ASIC1a activation and inhibits its maximal evoked response. ASIC1a antagonist-1 completely inhibits long-term potentiation (LTP) induction in CA3-CA1 pathway. ASIC1a antagonist-1 can be used for brain diseases and pathologies research .
    ASIC1a antagonist-1
  • HY-110097

    CNS 1102

    iGluR Neurological Disease
    Aptiganel hydrochloride (Cerestat) is a non-competitive NMDA receptor antagonist with neuroprotective effect.
    Aptiganel hydrochloride
  • HY-101356

    mGluR Neurological Disease
    CPCCOEt is a low affinity, selective, non-competitive and reversible antagonist of metabotropic glutamate receptor 1b (mGluR1b) .
    CPCCOEt
  • HY-116530

    9-CP-Ade mesylate

    Adenylate Cyclase Others Neurological Disease
    9-Cyclopentyladenine monomethylsulfonate (9-CP-Ade mesylate) is a stable non-competitive adenylate cyclase inhibitor with cell permeable properties .
    9-Cyclopentyladenine monomethanesulfonate
  • HY-100792

    Bacterial Cancer
    URB602 is a selective monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL with IC50 of 28±4 μM through a noncompetitive mechanism.
    URB602
  • HY-12503
    CFM-2
    1 Publications Verification

    iGluR Neurological Disease Cancer
    CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .
    CFM-2
  • HY-103391

    Amino Acid Decarboxylase Metabolic Disease
    Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease .
    Qc1
  • HY-N9919

    Others Others
    Glyasperin C is a potent and reversible noncompetitive inhibitor of neuraminidase with an IC50 of 20% at 200 μM. Glyasperin C is a polyphenol isolated from the roots of Glycyrrhiza uralensis .
    Glyasperin C
  • HY-122142A

    S-2366 hydrochloride

    APC Factor XI Biochemical Assay Reagents Others
    Pyr-Pro-Arg-pNA (S2366) hydrochloride is a chromogenic peptide substrate for Factor XI and Activated protein C (APC). Pyr-Pro-Arg-pNA hydrochloride can induce noncompetitive inhibition of factor XI activation through occupancy of the active site of the factor XIa-light chain. Pyr-Pro-Arg-pNA hydrochloride can be used for measurement of APC amidolytic activity .
    Pyr-​Pro-​Arg-​pNA hydrochloride
  • HY-110132

    CCR Inflammation/Immunology
    JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2 .
    JNJ-27141491
  • HY-124101

    Histone Methyltransferase Cancer
    PDAT is a noncompetitive indolethylamine-N-methyltransferase (INMT) inhibitor with a Ki of 84 μM for rabbit lung INMT (rabINMT) .
    PDAT
  • HY-N3394

    Others Infection
    Lecanoric acid is a histidine-decarboxylase inhibitor isolated from fungus. The inhibition by lecanoric acid is competitive with histidineand noncompetitive with pyridoxal phosphate. Lecanoric acid did not inhibit aromatic amino acid decarboxylase .
    Lecanoric acid
  • HY-N7536

    TRP Channel Others
    Voacangine is an antagonist for TRPV1 and TRPM8 but as an agonist for TRPA1 (EC50=8 μM). Voacangine competitively blockes capsaicin binding to TRPV1 (IC50=50 μM). Voacangine competitively inhibits the binding of menthol to TRPM8 (IC50=9 μM) and it shows noncompetitive inhibition against icilin (IC50=7 μM). Voacangine selectively abrogates chemical agonist-induced TRPM8 activation and did not affect cold-induced activation. Voacangine is an alkaloid isolated from the root bark of Voacanga africana .
    Voacangine
  • HY-B1413

    LIS 630

    Monoamine Oxidase Neurological Disease
    Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.
    Eprobemide
  • HY-111549

    Arf Family GTPase Cancer
    Bragsin1 is a potent, selective and noncompetitive inhibitor of the ArfGEF BRAG2, inhibits Arf GTPase activation, with an IC50 of 3 μM. Bragsin1 binds to PH domain of BRAG2, and is a noncompetitive interfacial inhibitor. Bragsin1 has no effect on the Sec7 domain of human ArfGEFs. Anti-cancer activity .
    Bragsin1
  • HY-N6793

    Microtubule/Tubulin Cancer
    Phomopsin A is a cyclic hexapeptide mycotoxin isolated from the fungus Phomopsis leptostomiformis. Phomopsin A is a noncompetitive inhibitor of the binding of radiolabeled vincristine to tubulin .
    Phomopsin A
  • HY-101809A

    iGluR Cardiovascular Disease
    CNS-5161 is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS 5161
  • HY-137673

    NADH Dehydrogenase Others
    2'-Deoxy-NAD+ is a noncompetitive inhibitor for NAD + with a Ki of 32 μM. 2'-Deoxy-NAD+ can be utilized as a substrate to study the ADP-ribosyl transfer reaction .
    2'-Deoxy-NAD+
  • HY-154964

    RSV Infection
    RSV L-protein-IN-2 (Compound A) is a noncompetitive RSV polymerase inhibitor (IC50: 4.5 μM). RSV L-protein-IN-2 shows antiviral activity against long RSV strains (EC50: 1.3 μM) .
    RSV L-protein-IN-2
  • HY-139158

    HIV Infection
    Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection .
    Ainuovirine
  • HY-122142

    S-2366

    APC Factor XI Biochemical Assay Reagents Others
    Pyr-Pro-Arg-pNA (S2366) is a chromogenic peptide substrate for Factor XI and Activated protein C (APC). Pyr-Pro-Arg-pNA can induce noncompetitive inhibition of factor XI activation through occupancy of the active site of the factor XIa-light chain. Pyr-Pro-Arg-pNA can be used for measurement of APC amidolytic activity .
    Pyr-​Pro-​Arg-​pNA
  • HY-P5158

    Adrenergic Receptor Others
    Conopeptide rho-TIA is a peptide derived from the venom contained in the predatory sea snail Conus tulipa, has highly selective and noncompetitive inhibitor at human α1B-Adrenergic Receptor. Conopeptide rho-TIA acts a competitive inhibitor at human α1A-Adrenergic Receptor and α1D-Adrenergic Receptor. Conopeptide rho-TIA binds to each subtype and may provide useful information for the development of novel α1-Adrenergic Receptor subtype-selective drugs .
    Conopeptide rho-TIA
  • HY-N1386R

    Reference Standards Tyrosinase Metabolic Disease
    2-Methoxycinnamic acid is a noncompetitive inhibitor of tyrosinase .
    2-Methoxycinnamic acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: